News

GBT and Biopharma-MEA Enter Agreement to Distribute Oxbryta® (voxelotor) in Six Middle Eastern Countries

September 08, 2020 16:05 ET | Source: Global Blood Therapeutics, Inc. 

More than 100,000 people age 12 years and older with sickle cell disease (SCD) in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it has entered into an exclusive agreement with Biopharma-Middle East and Africa (Biopharma-MEA) to distribute Oxbryta® (voxelotor) tablets in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates, collectively known as the Gulf Cooperation Council (GCC) region. There are estimated to be more than 100,000 people age 12 years and older in this region living with sickle cell disease (SCD).1

BIO-GBT-01_edited.png